The PrEPX Study

Project: Research

Project Description

The PrEPX Study enrolled over 5,000 participants between 2016 and 2018 in Victoria, South Australia and Tasmania. Participants were at risk of HIV infections and received daily tenofovir+ emtricitabine for HIV pre-exposure prophylaxis (PrEP). PrEP can reduce the risk of HIV transmission by 99% when taken with high adherence. The primary aim of the study was to reduce the incidence of new HIV infections at a population level. The study was enriched with a number of secondary endpoints.

A/Prof Wright received AUD$2,600,000 in total to fund the PrEPX study from The Victorian, South Australian and Tasmanian Departments of Health, from Alfred Health and from the Victorian AIDS Council. The funding was awarded to the Department of Infectious Diseases, Monash Central Clinical School.
Short titlePrEPX
StatusActive
Effective start/end date26/07/1631/12/19